Skip to main content

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms

Cantoni, Diego, Siracusano, Gabriel, Mayora-Neto, Martin, Pastori, Claudia, Fantoni, Tobia, Lytras, Spyros, Di Genova, Cecilia, Hughes, Joseph, Lopalco, Lucia, Temperton, Nigel J. and others. (2022) Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. Vaccines, 11 (1). Article Number 58. E-ISSN 2076-393X. (doi:10.3390/vaccines11010058) (KAR id:99404)

Abstract

Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic beginning in 2019, have highlighted the importance of effective vaccines to induce an antibody response with cross-neutralizing activity. COVID-19 vaccines have been rapidly developed to reduce the burden of SARS-CoV-2 infections and disease severity. Cross-protection from seasonal human coronaviruses (hCoVs) infections has been hypothesized but is still controversial. Here, we investigated the neutralizing activity against ancestral SARS-CoV-2 and the variants of concern (VOCs) in individuals vaccinated with two doses of either BNT162b2, mRNA-1273, or AZD1222, with or without a history of SARS-CoV-2 infection. Antibody neutralizing activity to SARS-CoV-2 and the VOCs was higher in BNT162b2-vaccinated subjects who were previously infected with SARS-CoV-2 and conferred broad-spectrum protection. The Omicron BA.1 variant was the most resistant among the VOCs. COVID-19 vaccination did not confer protection against hCoV-HKU1. Conversely, antibodies induced by mRNA-1273 vaccination displayed a boosting in their neutralizing activity against hCoV-NL63, whereas AZD1222 vaccination increased antibody neutralization against hCoV-229E, suggesting potential differences in antigenicity and immunogenicity of the different spike constructs used between various vaccination platforms. These data would suggest that there may be shared epitopes between the HCoVs and SARS-CoV-2 spike proteins.

Item Type: Article
DOI/Identification number: 10.3390/vaccines11010058
Additional information: For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.
Uncontrolled keywords: SARS-CoV-2; seasonal; HKU1; 229E; NL63; neutralisation, COVID-19
Subjects: Q Science > QR Microbiology > QR355 Virology
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Funders: Wellcome Trust (https://ror.org/029chgv08)
Medical Research Council (https://ror.org/03x94j517)
National Institute for Health Research (https://ror.org/0187kwz08)
Agence Nationale de la Recherche (https://ror.org/00rbzpz17)
Depositing User: Nigel Temperton
Date Deposited: 04 Jan 2023 17:23 UTC
Last Modified: 27 Feb 2024 11:53 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/99404 (The current URI for this page, for reference purposes)

University of Kent Author Information

Cantoni, Diego.

Creator's ORCID:
CReDIT Contributor Roles:

Di Genova, Cecilia.

Creator's ORCID: https://orcid.org/0000-0002-2121-0715
CReDIT Contributor Roles:

Temperton, Nigel J..

Creator's ORCID: https://orcid.org/0000-0002-7978-3815
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.